The US Food and Drug Administration (FDA) has approved an improved stool collection kit of Geneoscopy’s RNA-based colorectal ...

The earnings release highlighted strong GAAP revenue growth that beat consensus estimates, adjusted earnings per share (non-GAAP) that outpaced expectations, and an increase in adjusted operating ...

Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024: Revenue: $3.53 billion versus $3.22 billion ...

We primarily deployed the proceeds from selling Nilorn into Havas in the first quarter and into Fortrea during the second ...

There are a few important steps, but getting an online testosterone prescription is actually much easier than it might appear ...

Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held biopharmaceutical company focused ...

Andrew J. Oakley, Chairman of the Board of Onconetix, stated, “We continue to believe that the proposed transaction with Ocuvex, which brings a pipeline of commercial and late clinical stage ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the testing & diagnostics ...

Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...